← Leaderboards
Thomas E. Witzig
Mayo Clinic Coll Of Medicine, Rochester
$5,636,824
Attributed
$5,636,824
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.8M · FY2005–21$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$24,060,274 · 9
By mechanism
P50$21,012,438 · 4
R01$1,661,136 · 1
R21$1,000,559 · 2
P01$228,401 · 1
U10$157,740 · 1
Top collaborators
- George J Weiner9 shared
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- S Vincent Rajkumar$8,690,866
- Diane F Jelinek$8,218,570
- Neil E Kay$14,251,394
- Robert A Kyle$833,522
- Celine M Vachon$17,209,085
Others in their field
Top investigators on “S Lymphoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$171,980,034
- Richard L Schilsky · University Of Chicago$120,036,663
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$113,682,224
- Ronald T Mitsuyasu · University Of California Los Angeles$103,553,444
- Monica M Bertagnolli · Strang Cancer Prevention Center$61,393,123
- Charles A Coltman · Southwest Oncology Group$55,198,633
Research focus
S LymphomaLymphomaMalignant NeoplasmsClinical ResearchResearch PersonnelTumorClinical TrialsRelapseSignal TransductionSignal PathwayInhibitor/AntagonistNon-Hodgkin&AposResourcesBaseProgramsCellsApoptosisCell ProliferationMalignant - DescriptorPhosphotransferasesNeoplastic CellSpecialized Program Of Research ExcellenceIowaConduct Clinical Trials
Grant awards (34)
Lymphoma Specialized Program of Research Excellence (SPORE) in Human Cancer$2,298,345
P50 · FY2021 · CA
Lymphoma Specialized Program of Research Excellence (SPORE) in Human Cancer$2,420,487
P50 · FY2020 · CA
Project 3: Targeting Tumor Metabolism in Lymphoma$267,343
P50 · FY2020 · CA · contact PI
Lymphoma Specialized Program of Research Excellence (SPORE) in Human Cancer$2,325,000
P50 · FY2019 · CA
Project 3: Targeting Tumor Metabolism in Lymphoma$263,914
P50 · FY2019 · CA · contact PI
Lymphoma Specialized Program of Research Excellence (SPORE) in Human Cancer$47,881
P50 · FY2019 · CA
Lymphoma Specialized Program of Research Excellence (SPORE) in Human Cancer$2,500,000
P50 · FY2018 · CA
Project 3: Targeting Tumor Metabolism in Lymphoma$281,752
P50 · FY2018 · CA · contact PI
Lymphoma Specialized Program of Research Excellence (SPORE) in Human Cancer$2,375,000
P50 · FY2017 · CA
Project 3: Targeting Tumor Metabolism in Lymphoma$267,251
P50 · FY2017 · CA · contact PI
Specialized Programs of Research Excellence (SPORE) in Human Cancer$2,161,375
P50 · FY2016 · CA
Specialized Programs of Research Excellence (SPORE) in Human Cancer$2,133,360
P50 · FY2015 · CA
Specialized Programs of Research Excellence (SPORE) in Human Cancer$2,162,002
P50 · FY2014 · CA
Signal transduction inhibitor therapy for Lymphoma$325,779
R01 · FY2011 · CA · contact PI
P2 - Signal Transduction Inhibitor Therapy for Lymphoma$281,849
P50 · FY2011 · CA · contact PI
Signal transduction inhibitor therapy for Lymphoma$339,520
R01 · FY2010 · CA · contact PI
P2 - Signal Transduction Inhibitor Therapy for Lymphoma$297,339
P50 · FY2010 · CA · contact PI
Signal transduction inhibitor therapy for Lymphoma$336,563
R01 · FY2009 · CA · contact PI
Signal Transduction Inhibitor Therapy for Lymphoma$299,324
P50 · FY2009 · CA · contact PI
Signal transduction inhibitor therapy for Lymphoma$330,462
R01 · FY2008 · CA · contact PI
Signal Transduction Inhibitor Therapy for Lymphoma$309,922
P50 · FY2008 · CA · contact PI
Signal transduction inhibitor therapy for Lymphoma$328,812
R01 · FY2007 · CA · contact PI
Signal Transduction Inhibitor Therapy for Lymphoma$320,294
P50 · FY2007 · CA · contact PI
PI3K Pathway Inhibitors for Mantle Cell Lymphoma$239,509
R21 · FY2006 · CA · contact PI
PI3K Pathway Inhibitors for Mantle Cell Lymphoma$256,377
R21 · FY2005 · CA
Radioimmunotherapy for Lymphoma$251,682
R21 · FY2002 · CA
CHARACTERIZATION AND GROWTH OF CLONALLY RELATED MYELOMA CELL$228,401
P01 · FY2002 · CA
HEMATOLOGY$78,870
U10 · FY2002 · CA
HEMATOLOGY$78,870
U10 · FY2002 · CA
ENHANCEMENT OF LYMPHOMA RADIOIMMUNOTHERAPY BY CPG ODN$0
P50 · FY2002 · CA
Radioimmunotherapy for Lymphoma$252,991
R21 · FY2001 · CA
CHARACTERIZATION AND GROWTH OF CLONALLY RELATED MYELOMA CELL$0
P01 · FY2001 · CA
HEMATOLOGY$0
U10 · FY2001 · CA
CHARACTERIZATION AND GROWTH OF CLONALLY RELATED MYELOMA CELL$0
P01 · FY2000 · CA